TABLE 1.
Pharmacokinetic parameters for indinavir and nelfinavira
| Regimenb | C0 (ng/ml) | Clast (ng/ml)c | Cmax (ng/ml) | AUC (h · ng/ml) | t1/2 (h)d |
|---|---|---|---|---|---|
| Indinavir 800 mg q8h | 369 (<10-949) | 159 (85-506) | 5,508 (2,864-19,786) | 16,715 (5,705-28,084) | 1.3 (0.9-1.9) |
| Indinavir dosage (with nelfinavir) | |||||
| 1,000 mg q12h | <10 (<10-3,740) | 44 (<10-4,236) | 10,740 (3,379-18,210) | 38,863 (10,623-135,665) | 1.8 (1.1-2.4) |
| 1,200 mg q12h | 146 (58-5,215) | 95 (12-954) | 9,675 (6,154-18,198) | 26,901 (19,139-63,595) | 1.3 (1.0-2.4) |
| Nelfinavir plus indinavir | |||||
| Nelfinavir 1,250 mg q12h and indinavir 1,000 mg q12h | 1,779 (<187.5-4,579) | 1,554 (<187.5-5,540) | 5,826 (2,437-9,337) | 33,106 (15,434-81,717) | 3.6 (1.8-31) |
| Nelfinavir 1,250 mg q12h and indinavir 1,200 mg q12h | 1,805 (611-8,307) | 534 (189-4,270) | 5,641 (1,869-9,974) | 33,269 (10,494-89,539) | 2.4 (1.9-10.9) |
a
Values are medians (ranges).
b
The numbers of subjects included in the indinavir 1,000 mg q8h, 1,000 mg q12h, and 1,200 mg q12h analyses were 8, 10, and 7, respectively, and the numbers of subjects included in the nelfinavir with indinavir 1,000 mg and 1,200 mg q12h analyses were 9 and 7, respectively.
c
Clast is the concentration 8 h after the dose (for the q8h regimen) and 12 h after the dose (for the q12h regimen).
d
t1/2, half-life.